Sarepta Therapeutics | SRPT - Betriebsaufwand





Betriebsaufwand Veränderung Datum
Acadia Pharmaceuticals USD 272.68M 6.08M 2026-03
Agios Pharmaceuticals USD 130.77M 10.77M 2026-03
Alnylam Pharmaceuticals USD 898.54M 66.78M 2026-03
Amgen USD 4.78B 1.12B 2026-03
BioCryst Pharmaceuticals USD -553.84M 700.01M 2026-03
Biogen USD 1.96B 69.6M 2026-03
BioMarin Pharmaceutical USD 636.56M 39.61M 2026-03
Capricor Therapeutics USD 29.16M 2.87M 2025-12
Daiichi Sankyo JPY 468.57B 15.34B 2025-12
Eli Lilly USD 10.02B 285M 2026-03
Esperion Therapeutics USD 83.21M 14.06M 2025-12
Gilead Sciences USD 23.52B 18.55B 2026-03
Incyte USD 5.62B 4.5B 2026-03
Insmed USD 506.24M 7.31M 2026-03
Ionis Pharmaceuticals USD 364M 54M 2026-03
Moderna USD 1.78B 242M 2026-03
Nektar Therapeutics USD 40.9M 44.19M 2025-12
Neurocrine Biosciences USD 599.9M 22.3M 2026-03
Novavax USD 126.2M 23.62M 2025-12
Pfizer USD 90.1B 77.19B 2026-03
PTC Therapeutics USD 226.66M 19.64M 2026-03
Regeneron Pharmaceuticals USD 31.42B 28.44B 2026-03
Roche Holding CHF 21.01B 10.84B 2025-12
Sangamo BioSciences USD 33.87M 12.89M 2024-06
Sanofi EUR 9.31B 1.2B 2026-03
Sarepta Therapeutics USD 372.37M 480.65M 2026-03
Tectonic Therapeutic USD 21.52M 374K 2025-12
Ultragenyx Pharmaceutical USD 305M 16M 2026-03
Vertex Pharmaceuticals USD 1.85B 78.6M 2026-03